- A BDNF Val66Met Polymorphism and Ketamine-induced Rapid Antidepressant Action
-
Hashimoto
- Clin Psychopharmacol Neurosci.
- 2012 Apr;10(1):59-60.
No abstract available.
- The Impact of Personality Traits on Emotional Responses to Interpersonal Stress
-
Joo HJ, Yeon B, Lee KU
- Clin Psychopharmacol Neurosci.
- 2012 Apr;10(1):54-58.
OBJECTIVE: The aim of the present study was to examine the impact of personality traits on emotional responses to interpersonal stress. METHODS: Thirty-two healthy college students (18 men, 14 women; age...
- No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an Selective Serotonin Reuptake Inhibitor or Serotonin Norepinephrine Reuptake Inhibitor and the Brain-Derived Neurotrophic Factor (Val66Met) Polymorphism in Refracto
-
Yoshimura , Kishi T, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Katsuki A, Hayashi K, Iwata N, Nakamura J
- Clin Psychopharmacol Neurosci.
- 2012 Apr;10(1):49-53.
OBJECTIVE: This study examined the association between the brain-derived neurotrophic factor (BDNF) (Val66Met) polymorphism and the response to the addition of an atypical antipsychotic drug to a selective serotonin reuptake...
- Long-term Escitalopram Treatment in Korean Patients with Panic Disorder: A Prospective, Naturalistic, Open-label, Multicenter Trial
-
Choi KW, Woo JM, Kim YR, Lee SH, Lee SY, Kim EJ, Chung SK, Kang EH, Lee JH, Yu BH
- Clin Psychopharmacol Neurosci.
- 2012 Apr;10(1):44-48.
OBJECTIVE: Panic disorder is characterized by recurrent panic attacks, persistent concerns about additional attacks, and worry about the implications of the attack or significant changes in behavior related to the...
- In Vivo Evaluation of 11C-labeled Three Radioligands for Glycine Transporter 1 in the Mouse Brain
-
Zhang JC, Toyohara J, Wu J, Ishiwata K, Hashimoto
- Clin Psychopharmacol Neurosci.
- 2012 Apr;10(1):34-43.
OBJECTIVE: Glycine transporter 1 (GlyT-1) is one of the most attractive therapeutic targets for schizophrenia. There is great interest in developing radioligands for in vivo imaging of GlyT-1 in the...
- Altered Neuronal Markers Following Treatment with Mood Stabilizer and Antipsychotic Drugs Indicate an Increased Likelihood of Neurotransmitter Release
-
Scarr E, Dean B
- Clin Psychopharmacol Neurosci.
- 2012 Apr;10(1):25-33.
OBJECTIVE: Given the ability of mood stabilizers and antipsychotics to promote cell proliferation, we wanted to determine the effects of these drugs on neuronal markers previously reported to be altered...
- Diffusion Tensor Imaging Findings of White Matter Changes in First Episode Schizophrenia: A Systematic Review
-
Kuswanto C, Teh I, Lee TS, Sim K
- Clin Psychopharmacol Neurosci.
- 2012 Apr;10(1):13-24.
Earlier structural magnetic resonance imaging in schizophrenia have noted smaller white matter volumes in diverse brain regions and recent diffusion tensor imaging (DTI) studies have allowed better elucidation of changes...
- Are Cardiometabolic and Endocrine Abnormalities Linked to Sleep Difficulties in Schizophrenia? A Hypothesis Driven Review
-
Robillard , Rogers NL, Whitwell B, Lambert T
- Clin Psychopharmacol Neurosci.
- 2012 Apr;10(1):1-12.
Schizophrenia is a psychiatric disorder that includes symptoms such as hallucinations, disordered thoughts, disorganized or catatonic behaviour, cognitive dysfunction and sleep-wake disturbance. In addition to these symptoms, cardiometabolic dysfunction is...
